Recent developments to share with you

Good News! Kangchuanji Helps Partner Achieve China's First Generic Drug Consistency Evaluation for Co-Trimoxazole Injection

2024-08-21

According to the drug approval information released by NMPA, the Co-Trimoxazole Injection (specification: 5ml containing sulfamethoxazole 0.4g and trimethoprim 80mg) manufactured by Nanjing Jinling Pharmaceutical Factory of Jinling Pharmaceutical Co., Ltd. has passed the national generic drug quality and efficacy consistency evaluation (referred to as "consistency evaluation"), becoming the first manufacturer in China to have this intravenous formulation approved through the consistency evaluation. Kangchuanji provided R&D-related services for this product.

Co-Trimoxazole Injection is a combination antibacterial agent with good efficacy against infectious diseases such as Pneumocystis pneumonia (PCP), occupying a unique position in clinical practice. It is indicated for the treatment of Pneumocystis pneumonia in adults and children over 2 months of age; for the treatment of enteritis caused by susceptible strains of Shigella flexneri or Shigella sonnei in adults and children over 2 months of age; and for the treatment of severe or complicated urinary tract infections caused by susceptible strains of Escherichia coli, Klebsiella species, Enterobacter species, Morganella species, Proteus mirabilis, and Proteus vulgaris in adults and children over 2 months of age when oral administration of co-trimoxazole is not feasible and when the body is not sensitive to effective singleagent antibacterial agents used for urinary tract infections.

Keywords：

CDMO One-Stop Services for the Full Drug R&D and Manufacturing Lifecycle – Kangchuanji's Successful Participation in the Nanjing QianTuHui Conference

Good News! Kangchuanji Helps Partner Achieve China's First Approval for Olmesartan Medoxomil Orally Disintegrating Tablets

Related information

Bountiful Results | January–July 2026: Kangchuanji Pharmaceutical, in collaboration with multiple pharmaceutical companies, secured approval or passed the evaluation for 15 product specifications.

From January to July 2026, Nanjing Kangchuanji Pharmaceutical Technology Co., Ltd., leveraging its deep-rooted pharmaceutical R&D expertise and mature end-to-end CDMO capabilities, has provided robust support for the innovative R&D and commercialization of its partner companies, achieving further regulatory‑review milestones in collaboration with multiple partners. According to the NMPA’s public announcement of drug approval documents, a total of 12 drug products (covering 15 specifications) have been successfully approved or passed consistency evaluation, demonstrating significant results in translating innovative research into tangible outcomes.

2026-08-04

CDE Announcement: Updated Guidelines for Pediatric Medicines! “Technical Guidance on the Application of Physiologically Based Pharmacokinetic Models in Drug Development for Pediatric Populations (Draft for Public Comment)”

On August 17, the CDE released a draft of the “Technical Guidance for the Application of Physiologically Based Pharmacokinetic Models in Pediatric Drug Development” for public comment.

2024-10-27

Good news keeps pouring in: Jiuzhou Pharmaceutical’s Kangchuanji Pharmaceutical has helped its partner obtain marketing approval for Rosuvastatin–Ezetimibe Tablets (I).

2026-07-03

Please contact us for more detailed information.

Kangchuanji Pharmatech looks forward to working with you and jointly creating a bright future!

Nanjing Kangchuanji Pharmatech Co., Ltd.

Contact Us：18020149597（HR）
Recruitment Email:recruit@kcjpharma.com
Address: 2nd Floor, Building 5, No.199 Wenfang Road, Jiangning District, Nanjing, Jiangsu Province, China（Jiangning High-tech Park）

COOKIES

Our website uses cookies and similar technologies to personalize the advertising shown to you and to help you get the best experience on our website. For more information, see our Privacy & Cookie Policy

COOKIES

required

These cookies are necessary for basic functions such as payment. Standard cookies cannot be turned off and do not store any of your information.

analyze

These cookies collect information, such as how many people are using our site or which pages are popular, to help us improve the customer experience. Turning these cookies off will mean we can't collect information to improve your experience.

Feature

These cookies enable the website to provide enhanced functionality and personalization. They may be set by us or by third-party providers whose services we have added to our pages. If you do not allow these cookies, some or all of these services may not function properly.

advertise

These cookies help us understand what you are interested in so that we can show you relevant advertising on other websites. Turning these cookies off will mean we are unable to show you any personalized advertising.

南京康川济医药科技有限公司

Recent developments to share with you

Good News! Kangchuanji Helps Partner Achieve China's First Generic Drug Consistency Evaluation for Co-Trimoxazole Injection

COOKIES

COOKIES